Get started
Work

ILLUMINATE-A, une étude de phase 3 du lumasiran, un ARNi thérapeutique expérimental, chez les enfants et les adultes atteints d’hyperoxalurie primaire de type 1

Year: 2020
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.nephro.2020.07.036
Authors: S. Garrelfs, Y. Frishberg, S. Hulton, M. Koren, W. O’Riordan, P. Cochat, G. Deschenes, H. Shasha-Lavsky, J. Saland, W. van’t Hoff, D. Fuster, D. Magen, S. Moochhala, G. Schalk, E. Simkova, J. Groothoff, D. Sas, K. Meliambro, J. Lu, P. Garg, J. Gansner, T. McGregor, J. Lieske
Institutions: Emma Kinderziekenhuis, Amsterdam University Medical Centers, University of Amsterdam, Shaare Zedek Medical Center, Birmingham Children's Hospital, Jacksonville Center for Clinical Research, Université de Lyon, Hospices Civils de Lyon, Hôpital Robert-Debré, Western Galilee Hospital, Icahn School of Medicine at Mount Sinai, Great Ormond Street Hospital, University of Bern, University Hospital of Bern, Rambam Health Care Campus, The Royal Free Hospital, University of Bonn, Al Jalila Foundation, Mayo Clinic, Alnylam Pharmaceuticals (United States)
Language: French
Field: Medicine
Open Access status: closed
OpenAlex ID: W3087005271
FWCI:
Cites:
Cited by:
Related to: 10